T1	Person 0 3	Age
T2	Value 4 15	>/=18 years
T3	Temporal 16 28	at screening
R1	Has_value Arg1:T1 Arg2:T2	
R2	Has_temporal Arg1:T1 Arg2:T3	
T4	Qualifier 44 59	relapsing forms
T5	Condition 63 87	multiple sclerosis (RMS)
R3	Has_qualifier Arg1:T5 Arg2:T4	
T6	Qualifier 93 107	active disease
R4	Has_qualifier Arg1:T5 Arg2:T6	
T7	Observation 131 147	imaging features
T8	Observation 119 127;139 147	clinical features
*	OR T8 T7
T9	Scope 119 147	clinical or imaging features
R5	Has_scope Arg1:T5 Arg2:T9	
T10	Multiplier 153 165;183 204	at least one over a 6-month period
T11	Condition 166 182	clinical relapse
R7	Has_multiplier Arg1:T11 Arg2:T10	
T12	Temporal 205 223	prior to screening
R6	Has_temporal Arg1:T11 Arg2:T12	
T13	Multiplier 237 249;379 401	at least one over a 3 months period
T14	Temporal 402 420	prior to screening
T15	Condition 250 280	T1 gadolinium-enhancing lesion
T16	Condition 305 314	T2 lesion
T17	Procedure 330 368	brain Magnetic Resonance Imaging (MRI)
T18	Qualifier 295 304	enlarging
T19	Temporal 284 287	new
*	OR T18 T19
T20	Scope 284 304	new and/or enlarging
R8	Has_scope Arg1:T16 Arg2:T20	
*	OR T15 T16
T21	Scope 250 368	T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI)
R9	Has_multiplier Arg1:T21 Arg2:T13	
T22	Scope 250 314	T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion
R10	AND Arg1:T22 Arg2:T17	
R11	Has_temporal Arg1:T21 Arg2:T14	
T23	Negation 426 428	no
T24	Multiplier 429 438	change of
T25	Procedure 439 475	Disease-Modifying Treatment(s) (DMT)
R12	Has_multiplier Arg1:T25 Arg2:T24	
R13	Has_negation Arg1:T24 Arg2:T23	
R14	AND Arg1:T21 Arg2:T25	
T26	Non-representable 476 546	compared to a previous MRI performed within 24 months before screening
T27	Scope 153 546	at least one clinical relapse over a 6-month period prior to screening; (ii) AND/OR at least one T1 gadolinium-enhancing lesion or new and/or enlarging T2 lesion as detected by brain Magnetic Resonance Imaging (MRI) performed over a 3 months period prior to screening with no change of Disease-Modifying Treatment(s) (DMT) compared to a previous MRI performed within 24 months before screening
R15	Has_scope Arg1:T5 Arg2:T27	
T28	Pregnancy_considerations 548 726	For women of childbearing potential: agreement to use an acceptable birth control method during the treatment period and for at least 12 months after the last dose of ocrelizumab
T29	Observation 751 785	beneficiary of healthcare coverage
